Compare KEQU & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KEQU | IPHA |
|---|---|---|
| Founded | 1906 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.3M | 165.3M |
| IPO Year | 1995 | 2014 |
| Metric | KEQU | IPHA |
|---|---|---|
| Price | $34.03 | $1.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | 3.2K | ★ 35.3K |
| Earning Date | 03-11-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.58 | N/A |
| Revenue | ★ $138,558,000.00 | N/A |
| Revenue This Year | N/A | $180.36 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $58.79 | ★ N/A |
| Revenue Growth | ★ 7.72 | N/A |
| 52 Week Low | $32.00 | $1.18 |
| 52 Week High | $46.57 | $2.71 |
| Indicator | KEQU | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 36.35 | N/A |
| Support Level | $32.99 | N/A |
| Resistance Level | $38.40 | N/A |
| Average True Range (ATR) | 1.20 | 0.00 |
| MACD | -0.18 | 0.00 |
| Stochastic Oscillator | 36.67 | 0.00 |
Kewaunee Scientific Corp is engaged in the design, manufacture, and installation of laboratory, healthcare, and technical furniture and infrastructure products. Its products include steel and wood casework, fume hoods, adaptable modular systems, movable workstations, stand-alone benches, biological safety cabinets, epoxy resin work surfaces, and sinks. The company operates through two reportable segments: Lab Products Group (LPG), which designs, manufactures, and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, flexible systems, work surfaces, workstations, workbenches, and computer enclosures, and the International segment.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.